|1.||Saoo, Kousuke: 6 articles (07/2009 - 11/2003)|
|2.||Imaida, Katsumi: 6 articles (07/2009 - 11/2003)|
|3.||Yokohira, Masanao: 6 articles (07/2009 - 11/2003)|
|4.||Kamataki, Tetsuya: 5 articles (07/2009 - 11/2003)|
|5.||Takeuchi, Hijiri: 5 articles (07/2009 - 11/2003)|
|6.||Wolf, P: 4 articles (09/2011 - 10/2000)|
|7.||Hofer, A: 4 articles (09/2011 - 10/2000)|
|8.||Yamakawa, Keiko: 4 articles (07/2009 - 03/2006)|
|9.||Matsuda, Yoko: 4 articles (07/2009 - 03/2006)|
|10.||Marzano, Cristina: 4 articles (11/2005 - 09/2002)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
09/01/2011 - "Treatment responses were analysed in terms of Psoriasis Area and Severity Index (PASI) improvement, including complete remission (CR) and reduction of PASI by at least 90% (PASI 90) or 75% (PASI 75), at treatment completion for PUVA (median time 10·3 and 9·2 weeks, for 8-MOP and 5-MOP, respectively) and at week 12 for biologics. "
09/01/1979 - "Prior testing with this light source and topically applied methoxsalen achieved excellent results in psoriasis. "
10/01/2006 - "Our data indicate that in bath-PUVA treatment the use of a high (5 mg/L) methoxsalen concentration is substantially more effective in clearing chronic plaque-type psoriasis than a low (1 mg/L) concentration."
09/01/1980 - "A combination of methoxsalen and high-intensity ultraviolet A radiation was employed and its therapeutic efficacy in nail psoriasis ascertained. "
11/01/1977 - "Oral methoxsalen when used in the higher dose followed by sun exposure is an effective treatment for psoriasis. "
|2.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/01/1991 - "Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL). "
09/01/2001 - "Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells."
07/01/1989 - "Methoxsalen and extracorporeal photoactivation in the treatment of cutaneous T-cell lymphoma."
02/01/2000 - "Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing agent 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in treatment of selected T-cell mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. "
11/01/1998 - "Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in the treatment of several T-cell-mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. "
04/01/2005 - "The results of the study indicate that at least 18 courses of local PUVA within 6 weeks, with a cumulative dose of 87 J/cm(2), are required to induce a significant decrease in the disease severity and an improvement in the infiltration of plaques due to 8-MOP gel at a concentration of 0.01% when treating chronic recurrent palmoplantar dermatoses."
01/01/1989 - "The administration of 8 - methoxypsoralen combined with UV-A exposure (PUVA) was found to be effective in a case of progressive pigmented purpuric dermatosis (PPPD). "
04/01/2005 - "Aims In this study, the efficacy of topical PUVA treatment with 8-methoxypsoralen (8-MOP) gel was compared with placebo plus UVA in chronic recurrent palmoplantar dermatoses. "
08/01/2015 - "8-Methoxypsoralen (8-MOP) is a well established drug in the treatment of various skin diseases. "
12/01/2012 - "The bifunctional compound furocumarin 8-methoxypsoralen (8-MOP) is widely used in the treatment of various inflammatory skin diseases. "
11/01/2015 - "Photochemochemotherapy with 8-methoxypsoralen and UV-A light (PUVA) is a well-established treatment for mycosis fungoides (MF), although evidence for this therapy by means of prospective studies is scarce. "
01/01/2005 - "We retrospectively evaluated the outcomes of bath-water delivery of 8-MOP (1 mg l(-1)) in 16 patients with early stage mycosis fungoides. "
01/01/1979 - "Nine patients with stages 2 or 3 mycosis fungoides (MF) and one with Sézary's syndrome were treated with oral methoxsalen and long-wave ultraviolet light. "
11/12/1977 - "Six patients with mycosis fungoides were treated with methoxsalen and long-wave ultraviolet light. "
08/01/1976 - "The cutaneous manifestations of mycosis fungoides have been successfully treated in nine patients for 16 to 28 months with oral methoxsalen and subsequent irradiation with longwave ultraviolet light. "
02/01/2012 - "This study determined the threshold doses for 'solar erythema' and for phototoxic responses to 8-methoxypsoralen (8-MOP) in white skin Hanford and grey skin Yucatan miniature swine. "
03/01/2003 - "Methoxsalen-UV-A erythema exhibited a broad plateau between 96 and 144 hours, with most subjects at peak erythema at 120 hours. "
03/01/2003 - "The PUVA erythema after 15-minute methoxsalen immersion exhibited a broad peak, with the lowest median minimal phototoxic dose (MPD) at 96, 120, and 144 hours after UV-A irradiation. "
03/01/2003 - "The characteristics of PUVA erythema following 15- and 5-minute immersion in methoxsalen was determined. "
03/01/2003 - "The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion."
|4.||DNA (Deoxyribonucleic Acid)
|7.||Polymethyl Methacrylate (Sol)
|9.||4-Aminobenzoic Acid (4 Aminobenzoic Acid)
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Phototherapy (Light Therapy)